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Abstract
Background: It is recognized that cancer cells exhibit highly elevated glucose metabolism compared to non-tumor cells. We
have applied in vivo optical imaging to study dynamic uptake of a near-infrared dye-labeled glucose analogue, 2-
deoxyglucose (2-DG) by orthotopic glioma in a mouse model.
Methodology and Principal Findings: The orthotopic glioma model was established by surgically implanting U87-luc
glioma cells into the right caudal nuclear area of nude mice. Intracranial tumor growth was monitored longitudinally by
bioluminescence imaging and MRI. When tumor size reached .4 mm diameter, dynamic fluorescence imaging was
performed after an injection of the NIR labeled 2-DG, IRDye800CW 2-DG. Real-time whole body images acquired
immediately after i.v. infusion clearly visualized the near-infrared dye circulating into various internal organs sequentially.
Dynamic fluorescence imaging revealed significantly higher signal intensity in the tumor side of the brain than the
contralateral normal brain 24 h after injection (tumor/normal ratio, TNR =2.860.7). Even stronger contrast was achieved by
removing the scalp (TNR =3.761.1) and skull (TNR =4.261.1) of the mice. In contrast, a control dye, IRDye800CW
carboxylate, showed little difference (1.160.2). Ex vivo fluorescence imaging performed on ultrathin cryosections (20 mm) of
tumor bearing whole brain revealed distinct tumor margins. Microscopic imaging identified cytoplasmic locations of the 2-
DG dye in tumor cells.
Conclusion and Significance: Our results suggest that the near-infrared dye labeled 2-DG may serve as a useful
fluorescence imaging probe to noninvasively assess intracranial tumor burden in preclinical animal models.
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Introduction
Glioblastoma multiform (GBM) is a lethal intracranial cancer,
which exhibits a relentless malignant progression and is highly
resistant to conventional multimodal therapies. GBM is charac-
terized by the nature of extensive infiltration into surrounding
normal brain tissue, which results in incomplete tumor resection
and consequent recurrence [1,2]. It is imperative to improve
diagnostic imaging to evaluate intracranial tumor growth and
therapeutic responses. Optical imaging has been rapidly adapted
to cancer research. Recently, optical imaging using fluorescent dye
labeled tumor-specific molecules has been successfully applied to
imaging glioma in preclinical animal models based on overex-
pression of such markers in glioma [3–5]. In the clinic, several
recent studies have demonstrated the ability of fluorescence
imaging to facilitate radical resection of GBM during surgery
[6–8]. Promising results reported by Stummer, et al. have shown
that gross total resection of glioma guided by intraoperative
fluorescence imaging is associated with improved prognosis of the
patients with a median survival of 15–18 months, compared to
10–12 months after a subtotal resection or about 6 months after
biopsy alone [8].
It is well recognized that cancer cells exhibit highly elevated
glucose metabolism and up-regulated glucose transporters
(GLUTs) compared to non-tumor cells. On this basis,
18FDG,
the glucose analogue, has been used as the most common PET
radiotracer to visualize clinical tumors and their metastases.
However, a drawback of
18FDG PET for brain tumors is strong
background signals of normal brain tissues, which often
compromise the ability to diagnose the brain tumors. Moreover,
PET has a low spatial resolution in spite of high sensitivity.
Optical imaging by visualizing fluorescently labeled tumor cells
PLoS ONE | www.plosone.org 1 November 2009 | Volume 4 | Issue 11 | e8051has recently emerged as an attractive approach to facilitate
identification of infiltrative tumors and sentinel lymph node
metastases [9–14]. Alternative to radioactive deoxyglucose,
fluorescent derivatives of 2-DG, e.g.,2 - [ N-(7-nitrobenz-2-
oxa-1,3-diazol-4-yl)amino]-2-deoxy-D-glucose (2-NBDG) have
shown a greater tendency to be delivered and trapped in tumor
cells [15,16]. However, the short wavelength of 2-NBDG
(excitation, 475 nm; emission, 550 nm) limits its applications
for in vivo imaging. Near infrared fluorescence has several
advantages over the use of visible fluorophores including deeper
penetration due to less tissue absorption and scattering of light,
and minimal autofluorescence. IRDye800CW 2-DG (Li-Cor
Bioscience), a NIR dye conjugated with 2-deoxyglucose (peak
excitation 785 nm, emission 810 nm), has recently been
developed and demonstrated as a tumor-targeting optical
contrast agent in various tumors implanted subcutaneously in
mice, which can be visualized in vivo by fluorescence imaging
[17,18]. Moreover, arecentstudy of pharmacokinetics has shown
that there is essentially no retention of the dye in normal mouse
brain 24 h after injection [19]. Thus, the 2-DG NIR dye may
serve as an ideal contrast agent for optically imaging brain
tumors.
In this study, we first applied bioluminescence imaging (BLI)
and MRI to assess non-invasively intracranial tumor growth in an
orthotopic glioma model in nude mice. We then exploited
IRDye800CW 2-DG for dynamic in vivo imaging of these brain
tumors. In vivo observations were validated by both ex vivo
fluorescence imaging of cryosections of tumor bearing brain
tissues and histological staining. Finally, fluorescence microscopic
studies were performed to identify locations of the 2-DG dye in
tumors and normal brain.
Results
Immunohistochemical study showed extensive expression of
luciferase in the U87-luc cells of intracranial tumor tissues
(Fig. 1A). Longitudinal BLI studies revealed a weak signal initially
11 days after tumor implantation, which became stronger on
follow-up to day 24 (Fig. 1B). The mean light intensity detected on
day 24 for the group of tumor bearing mice was significantly
greater than on day 11 (16610
7 versus 11610
6 photons/s;
p,0.05). MRI studies based on T2-weighted and T1-weighted
contrast enhanced images confirmed an intracranial tumor located
in the right side of the brain of each animal (Fig. 1C). A significant
correlation was found between BLI signal and actual tumor
volume measured by MRI (r=0.8, p,0.05; Fig. 1D). Tumor
volume determined on the last MRI scan (one day before the in
vivo fluorescence imaging) varied from 42 to 136 mm
3 in the seven
animals. There was no significant difference in tumor volume
between the group receiving the 2-DG dye or the control dye
when the in vivo fluorescence imaging was performed (p=0.5).
The real-time whole body NIR optical imaging, acquired
immediately after i.v. injection of the 2-DG dye, IRDye 800CW 2-
DG (15 nmol/mouse) or the control dye, IRDye 800CW
carboxylate (15 nmol/mouse), visualized the first pass of the dye
sequentially through various organs and tissues (Fig. 2). By
narrowing the field of view (FOV), brain-focused in vivo imaging
showed dynamic changes in fluorescence signal intensity on the
tumor side of the brain (right) in comparison with the contralateral
normal brain (left). Relatively higher signal intensity was observed
for the 2-DG dye in both sides of the brain than the rest of the
mouse body (Fig. 3). Time course curves showed that the signal
intensity in both sides of the brain had a maximum value of
Figure 1. BLI and MRI monitoring of intracranial growth of U87 glioma in a mouse. A. Immunostaining with anti-luciferase antibody
showed extensive expression of luciferase in tumor tissues. B. BLI showed increasing light intensity in the mouse brain over time. C. Transaxial MRI
detected an intracranial tumor on consecutive slices (arrows) based on both T2- weighted and T1-weighted contrast enhanced MRI, which was found
to grow in size on the follow-up study (84 mm
3 on day 17, 136 mm
3 on day 24). D. A good correlation between the BLI signal and actual intracranial
tumor volume was observed (r=0.8, p,0.05).
doi:10.1371/journal.pone.0008051.g001
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760.2610
7 counts/s 10 min after injection, and gradually
washed out over 4 h. There was no significant difference in signal
intensity between the two sides of the brain during the first 4 h
after injection (Figs. 3A and 4; p.0.3). Twenty four hours later,
a dramatic drop in signal intensity was observed. However,
significantly higher light signal was clearly seen in the tumor side
of the brain than the contralateral normal side (1.8610
560.2610
5
versus 0.7610
560.4610
5;p ,0.05; Fig. 4A). A mean tumor/
normal ratio (TNR) for the group of 4 tumors was 2.860.7
(Fig. 4B). In contrast, the control dye showed little difference
(0.54610
560.1610
4 versus 0.43610
560.3610
4; TNR =1.16
0.3; Fig. 4B and C). To confirm that the signal originated from the
brain tumor, we performed surgical procedures to reflect scalp and
further remove skull to expose the brain. A brighter and more
focused light signal emitted from the region of the tumor
implantation was seen (Fig. 3A). Stronger contrast was achieved
by reflecting the scalp (TNR =3.761.1) and further removal of
the skull of the mouse revealed a highest TNR of 4.261.1 (Fig. 4C).
For the control dye, similar to the observation in the intact
animals, no significant difference was found (TNR =1.460.2 and
1.460.1, respectively; Fig. 4C). Comparison of in vivo BLI and 2-
DG fluorescence imaging of intracranial tumors also showed a
strong linear correlation albeit in a small number of animals (n=4;
r=0.9; Fig. 4D). After sacrificing the mice, the whole brain was
dissected and ultrathin sections (20 mm) of tumor bearing brain
were imaged using the same fluorescence imaging system as used
for in vivo. Most intriguingly, distinct tumor margins, even the
tracks of migration of small number of tumor cells, were identified
based on the fluorescence images, which correlated well with
histological staining of the tumor (Fig. 5). In good agreement with
in vivo imaging data, uptake of the 2-DG dye was found to be
significantly higher in tumor than the contralateral normal brain
(TNR =3.761.1; p,0.01; Fig. 5I). Finally, fluorescence micros-
copy showed more uptake of the 2-DG dye in tumor regions,
compared to the control dye (Fig. 6). Co-registration of the NIR
signal with the DAPI stained nuclei showed a cytoplasmic
localization of the 2-DG dye (Fig. 6G).
Discussion
We have demonstrated the feasibility of using the NIR dye
labeled 2-deoxyglucose, IRDye800CW 2-DG, for in vivo fluores-
cence imaging of orthotopic glioma in a mouse model (Fig. 3). Ex
vivo fluorescence imaging of tumor sections and microscopic
imaging confirmed significantly higher accumulation of the 2-DG
dye in intracranial tumors than in normal brain. Good correlations
Figure 2. In vivo real-time near infrared imaging of a mouse. A series of whole body images was acquired before and after injection of near
infrared dye labeled 2-DG, IRDye800CW 2-DG, via a mouse tail vein. Selected images captured the first pass perfusion of the dye into various internal
organs: heart and lung area at 1.2 s, brain and upper limbs at 2.5 s, kidney at 4.5 s, etc. Principal Component Analysis of the kinetics was used to
identify tissue regions based on DyCE software as shown in the color presentation (top left) and representative time courses (bottom right).
doi:10.1371/journal.pone.0008051.g002
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evaluation of intracranial tumor burden (Figs. 1 and 4D).
Small animal imaging has been increasingly adapted for
preclinical cancer research. In vivo imaging promises greater
efficiency since each animal serves as its own control and multiple
time points can be examined sequentially. In particular,
multimodal imaging approaches provide comprehensive informa-
tion about both tumor anatomy and pathophysiology and even
molecular mechanisms [4,20–23]. In this study, we combined
optical imaging (bioluminescence and fluorescence imaging) with
MRI to study longitudinal development of intracranial tumors and
their uptake of a glucose analogue, 2-DG. There was good
agreement between increased BLI signal intensity over time and
enlarged tumor volume measured by MRI, as also reported by
others previously for intracranial tumors in rodent models [4,24].
Thus, the cheap, fast and high-throughput BLI seems to be just as
effective in monitoring the deep-seated orthotopic tumor models
as the expensive and time consuming MRI. However, BLI does
not provide anatomic details due to the poorer spatial resolution
and limited depth of light penetration. Recent progress in BLI
tomography should facilitate three-dimensional analysis. In
addition to providing detailed anatomic structure, MRI is also
useful to obtain pathophysiological information, i.e., tumor
vascular perfusion and permeability, oxygenation, and apoptosis
or necrosis, though not reported here.
Fluorescence imaging can be used to evaluate small reporter
molecule pharmacokinetics, avoiding the need for genetic
modification of cells. In particular, near infrared fluorescence
(NIR) imaging has found a greater potential for clinical application
because of its long wavelength (650–900 nm), where light
absorbance and scattering are significantly lower, and autofluo-
rescence of normal tissues is also greatly reduced [25]. In view of
this approach, various target-specific NIR conjugates have been
reported for targeting tumor imaging, e.g., tumor integrin, avb3
[4], tumor growth factors or their receptors [18,26–30],
glycoprotein [31], or tumor specific protease [21]. Successful
applications in various preclinical tumor models have been
reported, though most of these studies were performed on surface
Figure 3. Dynamic in vivo fluorescence imaging of the 2-DG dye uptake by intracranial glioma. A. After i.v. injection of IRDye800CW 2-DG
repeated in vivo fluorescence imaging was performed. During the first four hours, unmixed images showing stronger signal of the dye in the brain
area, but there was no obvious contrast between the tumor side of the brain and the normal brain. However, 24 h later, the light signal remained
only in the tumor side of the intact brain. Even better contrast was seen after reflection of the scalp or further removal of the skull. B. Normalized
emission spectra showing the near infrared 2-DG dye with a peak emission wavelength at 810 nm (red), while the background signal (white) was at
,770 nm. C. As a control of the 2-DG dye, IRDye800CW carboxyl was injected into a mouse bearing orthotopic glioma. No significant difference in
light intensity between the two sides of the brain was observed at any time points.
doi:10.1371/journal.pone.0008051.g003
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models, in particular, intracranial tumors, remains challenging. By
targeting the overexpressed avb3 in tumor, Hsu, et al. recently
reported visualization of orthotopic glioma of mouse in vivo by NIR
imaging via Cy5.5-RGD. Peak of tumor uptake was found 2 h post
injection and TNR =2.6 was achieved with a craniotomy [4].
More recent work with an orthotopic mouse brain tumor
McCann, et al. successfully applied fluorescent molecular tomo-
graphic imaging to monitor protease activity in tumor by using
protease activatable fluorescence, ProSense680 (peak light emis-
sion at 680 nm). By co-registering fluorescence images with MRI,
localization of the active protease in tumor was determined [5].
Here, we applied the commercially available NIR labeled 2-
deoxyglucose to imaging intracranial tumors based on the simple
mechanism of differential levels of glucose metabolism between
tumors and normal tissues. Tumor cells both require more
energy for their higher proliferation rate and utilize the
inefficient glycolytic pathway top r o d u c ee n e r g y .T h u s ,t u m o r
cells need more glucose compared to normal cells. On this basis,
18FDG has been used as the most common PET radiotracer to
visualize clinical tumors and their metastases. However,
18FDG
PET imaging of brain tumor is often compromised by strong
background signals of normal brain tissues. Due to the short half
life of fluorine-18 (,2 h), PET imaging is normally performed
within 1 h after injection of
18FDG. The lower contrast between
tumor and normal brain may be partly attributed to this timing,
at which a maximum ratio of uptake is not reached. Indeed, we
found no significant difference in light signal in the tumor side of
the brain versus the normal side of the brain during the first 4
hourspost injection. The peak tumor to normalratio was actually
observed at 24 h, which is consistent with a previous study of
subcutaneous U87 tumors using cy5.5 labeled D-glucosamine.
However, a control dye, cy5.5-NHS used in that study also
produced a high TNR [16]. Our study is also in a good
agreement with another study that detected essentially no
retention of IRDye800CW 2-DG in normal brain after 24 h
assessed by ex vivo imaging [19]. In addition to tumor diag-
nostic imaging, pyropheophorbide labeled 2-deoxyglucosamine
has shown a potential for photodynamic therapy on tumors
[32,33].
Figure 4. Time course of light intensity of in vivo fluorescence imaging of the 2-DG dye. Mean light intensity curves shown for the tumor
side (solid square) and the contralateral normal brain (open circle) of intact mice. A. For the 2-DG dye (n=4), the curves were essentially identical for
the first 4 h post injection, but after 24 h, there was a significant difference (1.8610
560.2610
5 versus 0.7610
560.4610
5;p ,0.05). B. In contrast, the
control carboxylated dye showed no difference during the whole course (n=3). C. Time course of tumor to normal tissue ratio (TNR) showing a
significantly higher TNR in the 2-DG dye group (mean =2.860.7; solid bar) versus the control group of the control dye (n=3; 1.160.3; open bar) 24 h
after injection (p,0.05). An even bigger TNR was obtained in the 2-DG group by removing the scalp (3.761.1) or skull (4.161.1). D. A strong linear
correlation was observed between light intensity of in vivo BLI and 2-DG NIR imaging of intracranial tumors (r=0.9).
doi:10.1371/journal.pone.0008051.g004
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DG dye distributed well into the whole tumor despite some
heterogeneity (Fig. 5). This observation may suggest delivery and
distribution of the 2-DG dye to the tumor does not need the BBB
disruption, which is the prerequisite condition for the dyes
currently used for neurosurgery. Indeed, uncoupling of tumor
vascular perfusion and permeability and uptake of FDG has been
reported previously [35,36]. However, it is still possible that the
dye first leaks out through the disrupted BBB, from which it
diffuses into the whole tumor. Further studies will be necessary
using earlier stage of tumors, when the Gd contrast leakage is not
obviously seen by T1-weighted contrast enhanced MRI, to prove
this hypothesis. Furthermore, the usefulness of the 2-DG dye to
stain the infiltrative tumor cells is limited by the tumor model used
in this study. The U87 tumor has relatively sharp tumor-brain
boundaries. GBM models showing more aggressiveness will be
needed to test the ability to stain the finger-shaped infiltrative
tumors. Instead of the established GBM cell lines, using surgically
resected tumor tissues directly from GBM patients and passing
them in animals will generate stable orthotopic GBM xenografts,
which show oncogene patterns very similar to primary tumors of
patients.
In summary, fluorescence imaging of deoxyglucose uptake in
more clinically relevant orthotopic glioma models has not yet been
reported. Our results may suggest an optimal time for imaging
brain tumors based on the glucose analogues. The near-infrared
dye labeled 2-DG may serve as a novel imaging probe to
noninvasively monitor intracranial tumor burden in preclinical
animal models. From a clinical perspective, development of NIR
labeled tumor-specific molecules may have the potential to identify
the infiltrating glioblastoma intra-operatively, and to improve the
extent of resection of selected tumors.
Materials and Methods
Orthotopic Glioma Xenografts
All animal procedures were approved by the Institutional
Animal Care and Use Committee of University of Texas
Southwestern Medical Center. Human glioma U87 MG cells
(ATCC, Manassas, VA, USA) were infected with a lentivirus
Figure 5. Ex vivo near infrared fluorescence imaging of ultrathin cryosections of tumor bearing brain tissues. Unstained coronal brain
sections (20 mm) containing tumor tissues were obtained immediately after the 24 h in vivo image for ex vivo imaging. For the tumors with 2-DG dye,
representative images for a larger (A) and a small (D) intracranial tumor showed predominant accumulation of the dye within the tumor mass. Tumor
mass was clearly delineated from the surrounding normal tissues. Even a track of migrated tumor cells was depicted in each case (arrows in A and D),
which correlated well with cresyl violet staining of the corresponding regions enlarged from B and E (arrows in C and F). Arrow heads refer to the
dentate gyrus. The control dye showed no significant difference between the tumor regions and the normal brain (G and H). Tumor/normal ratio
(TNR) of the 2-DG dye was significantly higher than that of the control dye (3.761.2 vs. 1.460.1; p,0.05; I).
doi:10.1371/journal.pone.0008051.g005
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clones were isolated. A ,1 cm long incision of skin was made
along the midline of the brain of an anesthetized nude mouse
(BALB/c nu/nu; Harlan, Indianapolis, IN). Using a high-speed
drill, a 1 mm burr hole of the skull was made in the right
hemisphere, anterior to the coronal fissure. About 5610
4 U87-luc
cells in 3 ml mixture of PBS and Matrigel (25%, BD Biosciences,
San Jose, CA) were injected directly into right caudal dienceph-
alon, 1.5 mm beneath the dura mater using a 32G Hamilton
syringe. Usage of a 32G fine needle minimizes tissue damage. The
burr hole was filled with bone wax and the scalp was closed with
sutures.
In Vivo BLI
BLI was initiated for monitoring intracranial tumor growth
about 10 days after tumor implantation and repeated once a week
using the IVIS Spectrum system (Caliper, Xenogen, Alameda,
CA). The tumor bearing mice (n=7) were anesthetized (isoflur-
ane/O2 in an induction chamber; isoflurane from Baxter
International Inc., Deerfield, IL) and a solution of D-luciferin
(120 mg/kg in PBS in a total volume of 80 ml; Biosynthesis,
Naperville, IL) was administered s.c. in the neck region. Anesthesia
was maintained with isoflurane (2%) in oxygen (1 dm
3/min). Five
minutes after luciferin injection, an array of various exposure time
(1, 5, 30, 60 s) was applied for image acquisition. Data were
quantified with the Living Imaging software by using absolute
photon counts (photons/s) in an ROI, manually drawn to outline
the BLI signal of the brain.
In Vivo MRI
Once a BLI signal was observed, MRI was performed to assess
tumor volume and growth by using a 4.7 T horizontal bore
magnet with a Varian INOVA Unity system (Palo Alto, CA). Each
mouse was maintained under general anesthesia (air and 2%
isoflurane). A 27 G butterfly (Abbott Laboratories, Abbott Park,
IL) was placed in a tail vein for contrast agent administration.
Pertinent image slice positions were based on fast sagittal
scout images. T1-weighted (TR =250 ms; TE =20 ms; slice
thickness =1.5 mm; FOV =25625; in plane resolution 195 mm)
and corresponding T2-weighted (TR =1900 ms; TE =80 ms)
spin-echo multislice coronal images were acquired. T1-weighted
contrast enhanced images were acquired after i.v. bolus injection
of the contrast agent Gd-DTPA-BMA (0.1 mmol/kg body weight;
Omniscan
TM, Amersham Health Inc., Princeton, NJ) through the
tail vein catheter. We determined tumor volume on T2-weighted
images by manually outlining the enhancing portion of the mass,
excluding congested CSF signal in ventricles, on each image by
using standard ‘‘browser’’ software provided with the Varian
Inova imaging system. The area measurements were automatically
calculated and multiplied by the MRI section thickness to calculate
a per-section tumor volume. The total tumor volume was obtained
by summing the volume calculations for all sections.
Near Infrared Fluorescence Imaging
In vivo real-time imaging of first pass perfusion. When
the intracranial tumors grew to larger than 4 mm in diameter
based on T2-weighted MRI, in vivo fluorescence imaging was
performed using a Maestro imaging system (CRI Inc. Woburn,
MA). Each mouse was anesthetized by i.p. injection of a ketamine/
xylazine cocktail (40 ml). A 27 G butterfly (Abbott Laboratories)
was placed in a tail vein for administration of the 2-DG dye,
IRDye800CW 2-DG (15 nmol/mouse in 150 ml saline, Li-Cor
Biosciences, Lincoln, NB) or a control dye, IRDye800CW
carboxylate (15 nmol/mouse in 150 ml saline, Li-Cor
Biosciences). Based on the methodology developed by Hillman
and Moore [37], an excitation filter (671–705 nm) was applied. A
series of whole body images was acquired before and after a bolus
injection of the 2-DG dye or the control dye. Typically, 5 frames/s
for the first 20 s, 2 frames/s for the next 30 s and 1 frame/s for the
rest of ,2 min were acquired. Image processing and data analysis
were performed using the DyCE software provided with the
Maestro software 2.8.
In vivo dynamic imaging of 2-DG uptake by intracranial
tumors. The brain-focused fluorescence images were acquired
before and 10 min, 30 min, 2 h, 4 h, and 24 h after injection of the
2-DG or the control dye. A set of filters specifically for NIR
Figure 6. Microscopic fluorescence imaging determined localization of the 2-DG dye. The unstained frozen sections of tumor bearing
brain tissues, also used in Fig. 5, were scanned under dark field (A and D). Near infrared signals (B and E) of the same fields detected with an infrared
filter were overlaid on the dark field images (C and F). Significantly higher signal was seen in tumor tissues of the mouse injected with the 2-DG dye,
compared to the one with control dye. Co-staining of nuclei of tumor cells with DAPI indicated cytoplasmic localization of the 2-DG dye (red; G).
doi:10.1371/journal.pone.0008051.g006
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applied. At each time point, the mouse was anesthetized by i.p.
injection of the ketamine/xylazine cocktail (40 ml). Immediately
after the last image at 24 h, the scalp of the mouse was surgically
reflected to expose the skull and a fluorescence image was
acquired. Before sacrificing the mouse, the skull was removed to
expose both sides of the brain tissues and a last in vivo image was
obtained. The whole surgical procedure and imaging was
completed within 15 min on the anesthetized animals and no
obvious bleeding was observed.
Ex vivo fluorescence imaging on cryosections of tumor
bearing brain. Immediately after sacrificing the animals, the
whole brains were dissected and embedded in O.C.T. and then
transferred to 280uC freezer. On the second day, a series of
coronal sections (20 mm) of the brain was cut. The frozen sections
containing tumor tissues were identified by cresyl violet staining.
The adjacent tissue sections were used for ex vivo fluorescence
imaging and fluorescence microscopic study, as described in detail
below. The ex vivo images were taken by using the same Maestro
system as used for in vivo studies. Typically, an exposure time of 2.5
s was applied for image acquisition.
Analysis of Fluorescence Imaging
Fluorescence images were obtained using the Maestro system
and processed with the Maestro software 2.8. The spectrum of
background signal (peak emission ,770 nm) was first obtained
from a mouse before the IRDye 800cw dye injection, while the
spectrum of IRDye 800cw dye (peak emission ,810 nm) was
detected from a solution of the dye in PBS (0.1 nmol/ml). The
spectra were then imported and used to unmix the NIR dye signal
from the background signal for both in vivo and ex vivo studies. The
whole set of in vivo images of an individual mouse, obtained before
and at various times after injection of the dye, was examined for
quantification. A common ROI was based on the most obvious
signal of the tumor, which was observed on the image of the skull-
deprived mouse 24 h after injection in each of the 2-DG animals,
was applied on both the tumor side and the contralateral normal
brain of each image. A total of photon counts (counts/s) in the
identical ROI was used for comparison of dynamic change in
signal intensity.
Histology and Fluorescence Microscope
Cresyl violet staining was performed on the cryosections
(20 mm). Tumor margins were determined under microscope
and correlated with the NIR light signal acquired by ex vivo
fluorescence imaging. The cryosections, unstained or counter-
stained by 49,6-diamidino-2- phenylindole (DAPI), were used for
fluorescence microscopy study. The NIR fluorescence signal was
detected using a Zeiss AxioObserver (Carl Zeiss MicroImaging,
Inc., Thornwood, NY) equipped with NIR filters. The NIR signals
were recorded and overlaid on either a dark image or an image
counterstained by DAPI of the same field. For luciferase staining,
monoclonal mouse antiluciferase mAb (1:150; AbD Serotec,
Raleigh, NC) and cy3-conjugated goat anti-mouse secondary
antibody (Jackson Immunoresearch Laboratories, West Grove,
PA) were used.
Statistical Analysis
Statistical significance was assessed using an ANOVA on the
basis of Fisher’s protected least significant difference (PLSD;
Statview; SAS Institute Inc., Cary, NC) or Student’s t tests.
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